Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CI 941

Known as: CI-941, CI941 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryThe MCF-7 cell S9 fraction and whole MCF-7 cells can mediate one-electron-redox cycling of doxorubicin, giving rise to… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2002
2002
The oxidative biotransformation of the anticancer drug 7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2-hydroxyethyl)amino… Expand
  • figure 2
  • figure 3
  • figure 4
  • figure 5
  • figure 6
1996
1996
The reversing effect of p-glycoprotein (Pgp) inhibitors on the multidrug resistance (MDR) phenotype is well established in a… Expand
1993
1993
The anthrapyrazole derivative biantrazole (7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2- hydroxyethyl)amino]ethyl]amino… Expand
1992
1992
The development of new drugs in early clinical trials is currently based upon the results of preclinical antitumour and toxicity… Expand
1992
1992
The pharmacokinetics of the anthrapyrazole CI-941 has been investigated in conjunction with the Phase I evaluation of the drug… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Highly Cited
1991
Highly Cited
1991
Thirty-one patients with advanced breast cancer were treated with CI941, an anthrapyrazole structurally related to mitoxantrone… Expand
Review
1991
Review
1991
  • I. Judson
  • Anti-cancer drugs
  • 1991
  • Corpus ID: 8473267
The anthrapyrazoles are a new class of intercalating agents which were synthesized in order to reduce the potential for free… Expand
1989
1989
This assay has facilitated the accurate determination of the pharmacokinetics of the drug in patients treated at the phase I… Expand
1987
1987
The anthrapyrazole CI941 is one of a new series of DNA complexing drugs which displays high level broad spectrum antitumour… Expand